Targoviste

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting
  2025-523659-73-00 5 2026-05-11 Obesity
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended
  2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
• PIONEER TEENS. A research study to compare a new medicine oral semaglutide to a dummy medicine in children and teenagers with type 2 diabete … Ended
  2023-506923-27-00 5 2020-10-30 Type 2 diabetes

Showing 1–5 of 5 trials